Treatment is highly dependent on genetic subtype: HNF1A-related MODY shows extreme sensitivity to sulfonylureas, while GCK-related MODY is not altered by medication and diabetes-related complications are rare [13]. Other genes account for 10% or fewer of MODY cases and may present with additional extra-pancreatic manifestations [13, 19, 20]. This evidence concerns the gene HNF1A and diabetes mellitus.